drugset / Trial / NCT05827146
Study of Hepalatide in Chronic Hepatitis D(CHD) Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A phase 2a clinical Study of Hepalatide for Injection in Subjects with Chronic Hepatitis D
Timeline
- Start
- 2023-10-07
- Primary completion
- 2024-01-30
- Completion
- 2024-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hepalatide | Protein / enzyme biologic | 2.1 mg | Subcutaneous |
| Subject | Hepalatide | Protein / enzyme biologic | 4.2 mg | Subcutaneous |
| Subject | Hepalatide | Protein / enzyme biologic | 6.3 mg | Subcutaneous |